1. Home
  2. NVRI vs STOK Comparison

NVRI vs STOK Comparison

Compare NVRI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enviri Corporation

NVRI

Enviri Corporation

HOLD

Current Price

$19.01

Market Cap

1.5B

Sector

Miscellaneous

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$31.75

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVRI
STOK
Founded
1853
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.9B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NVRI
STOK
Price
$19.01
$31.75
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$34.50
AVG Volume (30 Days)
1.4M
592.7K
Earning Date
02-24-2026
03-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.68
Revenue
$2,244,061,000.00
$205,632,000.00
Revenue This Year
N/A
$428.87
Revenue Next Year
$3.42
N/A
P/E Ratio
N/A
$46.60
Revenue Growth
N/A
1128.17
52 Week Low
$4.72
$5.35
52 Week High
$19.48
$38.69

Technical Indicators

Market Signals
Indicator
NVRI
STOK
Relative Strength Index (RSI) 55.33 52.53
Support Level $18.82 $30.75
Resistance Level $19.48 $33.28
Average True Range (ATR) 0.41 2.13
MACD -0.05 0.16
Stochastic Oscillator 50.00 52.59

Price Performance

Historical Comparison
NVRI
STOK

About NVRI Enviri Corporation

Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: